Janssen submits in EMA teclistamab for multiple mieloma under accelerated assessment
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
The EMA has released its list of applications for new medicines under evaluation by the CHMP in March 2022, confirming the submission of Janssen Cilag's teclistamab to the Agency, with a procedure start date on 17 February 2022.
The list also confirms that teclistamab will be evaluated under accelerated assessment timelines by the EMA.
Teclistamab is a bispecific antibody generated using Genmab's DuoBody technology that targets CD3 and B-cell maturation antigen (BCMA, tumor necrosis factor receptor superfamily member 17), for the potential IV or SC injectable treatment of multiple myeloma (MM).
Fonte: EMA applications for new medicines under evaluation by the CHMP - March 2022 (As a reminder, this list only includes information for medicines whose applications have been validated and evaluation started at the time the data was extracted).